LD Micro Invitational
June 6-7, 2017
Luxe Hotel Sunset Boulevard (Los Angeles)
The two-day, 7th annual LD Micro Invitational will feature company presentations from nearly 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. On the 7th, companies across three unique themes will present: Reg A+, "The Best of Buy-Side," and "Show Me the Money," which focuses solely on names with large insider buying over the past year. For more information on LD Micro, visit www.ldmicro.com
inTest (NYSE: INTT) designs, manufactures and markets thermal, mechanical and electrical products for use in the testing of integrated circuits (ICs) worldwide. The company operates through two segments: inTEST Thermal Solutions and inTEST Electromechanical Semiconductor Products. The inTEST Thermal Solutions segment offers ThermoStream temperature management tools, MobileTemp systems, ThermoChambers, Thermal Platforms, ThermoChuck precision vacuum platform assemblies, and Thermonics temperature conditioning products. Its products are used to test semiconductor wafers and ICs, electronic components and assemblies, mechanical assemblies, and electromechanical assemblies. For more information, visit the company's website at www.intest.com.
BioLargo (OTCQB: BLGO) delivers sustainable technology-based products that help solve some of the most widespread problems threatening the world's supply of water, food, agriculture, healthcare and energy. Its BioLargo Water (www.BioLargoWater.com) subsidiary showcases the award-winning Advanced Oxidation Systems, including its AOS Filter -- a product in development specifically designed to quickly and cost-effectively eliminate common yet toxic contaminants in water. BioLargo also owns a 50% interest in the award-winning Isan System. BioLargo's Odor-No-More subsidiary features award-winning products serving the pet, equine, military supply and consumer markets, including the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management. For more information, visit the company's website at www.biolargo.com.
AMMO (OTC: POWW) is a designer and manufacturer of products for law enforcement, hunting, military, sport shooting and self-defense. Founded in 2016, the company is headquartered in Scottsdale, Arizona, and has a manufacturing facility in Payson, Arizona. Founded with an aim of changing, innovating and invigorating the complacent munitions industry, AMMO promotes branded munitions that include the Jesse James line of munitions and accessories, SHIELD Series munitions for law enforcement, stealth subsonic munitions, and the OPS (One Precise Shot) defense line of munitions. For more information, visit the company's website at www.ammo-inc.com.
DarioHealth (NASDAQ: DRIO) is a digital health company that develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. The company is also pursuing patent applications in various jurisdictions covering the specific processes related to blood glucose level measurement, as well as various general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information, visit the company's website at www.mydario.com.
Ener-Core (OTC: ENCR) designs, develops and manufactures products that are based on Power Oxidizer technologies. The company's Power Oxidizer technology provides an alternative to traditional methods of destroying gaseous pollution by enabling industrial facilities to generate on-site power from their waste gases. Its products include Ener-Core PowerStation EC250 and Ener-Core Powerstation KG2-3G/GO, which have applications in landfills, distilleries, and wastewater treatment plants, as well as various industrial processes. The company sells its products directly, as well as through distributors in the United States and the Netherlands. For more information, visit the company's website at www.ener-core.com.
Moleculin Biotech (MBRX)
Moleculin Biotech (NASDAQ: MBRX) is a preclinical-stage pharmaceutical company that focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech was founded in 2015 and is headquartered in Houston, Texas. For more information, visit the company's website at www.molculin.com.
Intec Pharma (NTEC)
Intec Pharma (NASDAQ: NTEC) is a clinical-stage biopharmaceutical company that focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which has completed pPhase II clinical trials for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. For more information, visit the company's website at www.intecpharma.com.
Viking Therapeutics (VKTX)
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease Type Ia, and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy. For more information, visit the company's website at www.vikingtherapeutics.com.
Caladrius Biosciences (CLBS)
Caladrius Biosciences (NASDAQ: CLBS) is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset Type 1 diabetes. Product candidate CLBS03 is the subject of an ongoing phase 2 clinical trial (The Sanford Project: T-Rex study) in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration, as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency. The company's subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. For more information, visit the company's website at www.caladrius.com.
Sigma Labs (SGLB)
Sigma Labs (NASDAQ: SGLB) provides quality assurance software under the PrintRite3D® brand and is a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. The company's manufacturing and materials technologies and R&D solutions are designed for first-tier integrators like Boeing, GE Aviation, Honeywell Aerospace, and other commercial firms. Sigma Labs has current contracts with Federal Government and private industry clients to develop technologies from their conception through the design, building, and testing of prototype systems by integrating sensing, software, materials, and manufacturing technology risk-reduction solutions. For more information, visit the company's website at www.sigmalabsinc.com.
Stony Hill Corp. (STNY)
Stony Hill Corp. (OTC: STNY) is a vertically integrated company that focuses on various areas of the cannabis industry. The company explores and operates in the consumer, health and wellness, recreational, medical, media, and nutraceutical industries. Stony Hill Corp. is based in Los Angeles, California. For more information, visit the company's website at www.stonyhillcorp.com.
Fision (OTC: FSSN) develops and commercializes cloud-based software platform. The company's Fision marketing software centrally collects, stores, prioritizes, organizes, streamlines, integrates and distributes various digital marketing assets of its customers, including videos, images, logos and other brand materials, presentations, social content and other material marketing assets. It serves various industries, including banks and other financial institutions, insurance companies, hotels and other hospitality enterprises, healthcare and fitness companies, software and other technology companies, telecommunications companies, and other companies. The company licenses its proprietary software platform primarily through direct sales and independent national sales agencies. For more information, visit the company's website at www.fisiononline.com.
NeuroMetrix (NASDAQ: NURO) is a commercial-stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, visit the company's website at www.neurometrix.com.
Vitality Biopharma (VBIO)
Vitality Biopharma (OTC: VBIO) focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis in the United States. Its products in pipeline include Cannabosides - VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides - VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington's disease. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. For more information, visit the company's website at www.vitality.bio.
Arch Therapeutics (ARTH)
Arch Therapeutics (OTC: ARTH) is a life science medical device company that develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. Its primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics was founded in 2006 and is based in Framingham, Massachusetts. For more information, visit the company's website at www.archtherapeutics.com.
SilverSun Technologies (SSNT)
SilverSun Technologies (NASDAQ: SSNT) operates as a business application, technology and consulting company. The company resells enterprise resource planning financial accounting solution that provides various functions related to accounting, including financial reporting, accounts payable and accounts receivable, and inventory management, as well as offers training, technical support, and professional services. It also publishes and markets MAPADOC, an electronic data interchange software through a network of resellers. In addition, the company resells warehouse management system software, which controls the movement and storage of materials within an operation, and processes the related transactions. Further, it provides customer relationship management and business intelligence solutions. For more information, visit the company's website at www.silversuntech.com.
ITUS (NASDAQ: ITUS) funds, develops, acquires and licenses emerging technologies in the areas of biotechnology. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. ITUS Corporation was founded in 1982 and is based in Los Angeles, California. For more information, visit the company's website at www.ITUScorp.com.
eXp World Holdings (EXPI)
eXp World Holdings (OTC: EXPI) provides cloud-based real estate brokerage services for residential real estate market in the United states and Canada. The company facilitates buyers to search real-time property listings and sellers to list their properties through its website, and provides buyers and sellers access to a network of professional, consumer-centric agents, and brokers. It also offers access to collaborative tools and training services for real estate brokers and agents. In addition, eXp World Holdings provides marketing, training and other support services to its brokers and agents through a proprietary technology enabled services, and technology and support services contracted to third parties. For more information, visit the company's website at www.exprealty.com.
Origin Agritech (SEED)
Origin Agritech (NASDAQ: SEED) is an agricultural biotechnology company engaged in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services in the People's Republic of China. Origin Agritech was founded in 1997 and is headquartered in the Zhong-Guan-Cun (ZGC). As the first Chinese seed company with an in-house biotech research center, Origin leads the development of Genetically Modified (GM) technology. For more information, visit the company's website at www.originseed.com.cn.
Nano Dimension (NNDM)
Nano Dimension (NASDAQ: NNDM) develops three-dimensional (3D) printed circuit board printers. The company's 3D printers are used for printing multi-layer circuit boards. Nano Dimension's novel and proprietary technologies enable the use of conductive and dielectric inks for ultra-rapid prototyping of complex, high-performance multilayer circuit boards. The company's PCB 3D printer is the result of combining advanced breakthroughs in inkjet technology, 3D printing and nanotechnology. It also develops nano ink materials and dielectric ink. Nano Dimension was founded in 2012 and is headquartered in Ness Ziona, Israel. For more information, visit the company's website at www.nano-di.com.
MYnd Analytics (MYAN)
MYnd Analytics (OTC: MYAN) operates as a predictive analytics company. The company offers objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. The company uses its proprietary neurometric platform, PEER Online, to generate Psychiatric electroencephalogram (EEG) Evaluation Registry (PEER) reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. For more information, visit the company's website at www.myndanalytics.com.
Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals (OTC: CTXR) is a specialty pharmaceutical company that develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed phase 2b clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals was founded in 2007 and is headquartered in Cranford, New Jersey. For more information, visit the company's website at www.citiuspharma.com.
22nd Century (XXII)
22nd Century (NYSE: XXII) is a plant biotech company that provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company's website at www.xxiicentury.com.
Salem Media Group (SALM)
Salem Media Group (NASDAQ: SALM) operates as a multi-media company in the United States. It operates in three segments: Broadcast, Digital Media, and Publishing. The company owns and operates radio networks, which produce and distribute talk, news and music programming to radio stations, as well as sells commercial airtime to national advertisers and independent radio station affiliates. It also provides Christian and conservative-themed content, investing and health-themed content, e-commerce, audio and video streaming, and other resources digitally through Christian content websites, such as OnePlace.com, Christianity.com, Crosswalk.com, GodTube.com, GodVine.com, Jesus.org, BibleStudyTools.com, CrossCards.com, LightSource.com, iBelieve.com, CCMmagazine.com, and ChristianHeadlines.com; and conservative opinion websites. For more information, visit the company's website at www.salem.cc.
Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals (NASDAQ: SNOA) designs, produces and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue, skincare, and animal healthcare markets in the United States, Latin America, Europe and rest of the world. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores and bacteria, such as antibiotic-resistant strains. The company's Microcyn has received fourteen 510(k) clearances for use as a medical device in tissue care management. For more information, visit the company's website at www.sonomapharma.com.
Applied DNA Sciences (APDN)
Applied DNA Sciences (NASDAQ: APDN) provides biotechnology-based security solutions for supply chain security, brand protection and law enforcement applications in the United States, Europe and Asia. The company's principal supply chain security and product authentication solutions include SigNature DNA markers that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track and convict criminals; and SigNature T DNA markers, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs. For more information, visit the company's website at www.adnas.com.
AudioEye (OTC: AEYE) provides web accessibility solutions to Internet, print, broadcast and other media to people regardless of their network connection, device, location or disabilities in the United States. The company develops patented Internet content publication and distribution software that enables conversion of media into accessible formats, as well as allows for real time distribution on various Internet connected devices. It provides AudioEye Ally Platform, which consists of Digital Accessibility Platform and Ally Managed Service that are offered as an Internet cloud software as a service to website owners, publishers, developers and operators. For more information, visit the company's website at www.audioeye.com.
Simulations Plus (SLP)
Simulations Plus (NASDAQ: SLP) is a developer of drug discovery and development software, and a provider of preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Simulations Plus' software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies around the world. The company's innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into its software support its leading position as a software provider for physiologically-based pharmacokinetic modeling and simulation. For more information, visit the company's website at www.simulations-plus.com.
MassRoots, Inc. (MSRT)
MassRoots, Inc. (OTC: MSRT) operates a technology platform for the medical cannabis community in the United States. Its platform enables users to share their cannabis content, follow various dispensaries, and stay connected with the legalization movement, while its mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. The company's network is accessible as a free mobile application through the iOS App Store, the Amazon App Store, and the Google Play Marketplace, as well as a website at MassRoots.com. For more information, visit the company's website at www.massroots.com.
Polar Power (POLA)
Polar Power (NASDAQ: POLA) designs, manufactures and sells direct current (DC) power systems for applications in the telecommunications, military, electric vehicle charging, cogeneration, distributed power and uninterruptable power supply markets. It offers DC base power systems, DC hybrid power systems, and DC solar hybrid power systems. Polar Power installs, sells and services its products through its direct sales force, and a network of independent service providers and dealers. For more information, visit the company's website at www.polarpower.com.
Social Reality (SRAX)
Social Reality (NASDAQ: SRAX) is an advertising technology company providing the tools to automate digital marketers and content owners' campaigns across digital channels. SRAX's tools amplify performance and maximize profits for brands in the healthcare, CPG, automotive, wellness and lifestyle verticals through an omnichannel approach that integrates all aspects of the marketing experience into one platform. The company's machine-learning technology identifies brands' core consumers and their characteristics discovering new and measurable opportunities to target, reach and monetize audiences driving online and offline sales lift. For more information, visit the company's website at www.socialreality.com.
Ironclad Performance Wear (ICPW)
Ironclad Performance Wear (OTC: ICPW) designs and manufactures work wear for various construction, do-it-yourself, industrial, sporting goods, and general services markets. It offers technical gloves that are designed for individual user groups, such as carpenters, machinists, package handlers, plumbers, welders, roofers, oil and gas workers, mechanics, hunters, gardeners and do-it-yourself users; long and short sleeved shirts; and performance jackets, pants, shorts, reflective and polo shirts, underwear and tights. The company sells its products under the Ironclad brand through hardware stores, lumber yards, big box home centers, industrial distributors, and automotive and sporting goods retailers. For more information, visit the company's website at www.ironclad.com.
BioSig Technologies (BSGM)
BioSig Technologies (OTC: BSGM) is a development-stage medical device company that engages in developing a technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation. Its products under development includes PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP system, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The company is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and/or for arrhythmia treatments. For more information, visit the company's website at www.biosigtech.com.
Cancer Genetics (CGIX)
Cancer Genetics (NASDAQ: CGIX) develops, commercializes and provides molecular and biomarker-based tests and services in the United States, India and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. For more information, visit the company's website at www.cancergenetics.com.
Signal Bay (SGBY)
Signal Bay (OTC: SGBY) provides advisory, management and analytical testing services to the legalized cannabis industry in the United States. The company offers industry research, business and market intelligence, market forecasts and operational insights; and advisory and consulting services, including license application support, regulatory compliance, and operating services for current and prospect licensed cannabis businesses. Signal Bay also publishes industry information through online media, research reports, and publications, as well as operates CANNAiQ.com, a business to business information portal, and MarijuanaMath.com, a general interest informational website. For more information, visit the company's website at www.signalbay.com.
Aethlon Medical (AEMD)
Aethlon Medical (NASDAQ: AEMD) is a medical device company that focuses on creating devices that address unmet medical needs in cancer, infectious diseases, and other life-threatening conditions in the United States. The company develops Aethlon Hemopurifier, a medical device, which targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. For more information, visit the company's website at www.aethlonmedical.com.
Sphere 3D (ANY)
Sphere 3D (NASDAQ:ANY) delivers containerization, virtualization and data management solutions via hybrid cloud, cloud and on-premises implementations through its global reseller network and professional services organization. Together with its wholly owned subsidiaries, Overland Storage and Tandberg Data, has a strong portfolio of brands, including Glassware 2.0™, SnapCLOUD™, SnapScale®, SnapServer®, V3, RDX®, and NEO®, that are dedicated to helping customers achieve their information technology (IT) goals. For more information, visit the company's website at www.sphere3d.com.
FORM Holdings (FH)
FORM Holdings (NASDAQ: FH) develops, acquires and monetizes intellectual property worldwide. It operates through four segments: XpresSpa, Group Mobile, FLI Charge, and Intellectual Property. The company offers spa services and related products that include massage services for the neck, back, feet and whole body; nail care, such as pedicures, manicures, and polish changes; and travel products comprising neck pillows, blankets, massage tools and eye masks. As of December 31, 2016, the company operated 53 total locations in 40 terminals and 22 airports in 3 countries. For more information, visit the company's website at www.vringoip.com.
CytoDyn (OTC: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished phase 2 clinical trials with demonstrated antiviral activity in man. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from six phase 1 and phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. For more information, visit the company's website at www.cytodyn.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is engaged in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate currently being evaluated in a phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. For more information, visit the company's website at www.cellectar.com.
Genius Brands International (GNUS)
Genius Brands International (NASDAQ: GNUS) is a global media company developing, producing, marketing and licensing branded children's entertainment properties and consumer products for media distribution and retail channels. Led by award-winning creators and producers, Genius Brands distributes its content worldwide in all formats, as well as a broad range of consumer products based on its characters. Under its' wholly owned subsidiary, A Squared Entertainment, Genius Brands also represents third-party properties, including From Frank, a humor greeting card and product line, and Celessence Technologies, the world's leading micro encapsulation company, across a broad range of categories in territories around the world. For more information, visit the company's website at www.gnusbrands.com.
National HealthCare (NHC)
National HealthCare (NYSE: NHC) affiliates operate for themselves and third parties 76 long-term health care centers with 9,597 beds. NHC affiliates also operate 36 homecare programs, five independent living centers and 24 assisted living communities. NHC's other services include Alzheimer's units, long-term care pharmacies, hospice, a rehabilitation services company, and providing management and accounting services to third parties. For more information, visit the company's website at www.nhccare.com.
Legacy Education Alliance (LEAI)
Legacy Education Alliance (OTCQB: LEAI) is an international leader in providing practical, high-quality and value-based education training on the subjects of personal finance, entrepreneurship, real estate and financial markets investing strategies and techniques. Founded in 1996, the company has become a global enterprise supported by about 200 employees and has cumulatively served over 2 million students from more than 150 countries and territories. Legacy Education Alliance offers training through various brands, including Rich Dad® Education, Rich Dad® Stock Education, Making Money from Property with Martin RobertsTM, Brick Buy BrickTM, Building Wealth, Robbie Fowler Property AcademyTM, Women in WealthTM, The Independent WomanTM and Trade Up Investor EducationTM. For more information, visit the company's website at www.legacyeducationalliance.com.
Exactus (OTC: EXDI) is a life science company that engages in developing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. It develops products to make patient data available to healthcare providers in a way that is unmatched. Exactus addresses healthcare gaps with easy-to-use, portable devices that reduce the time required to return analysis on patient blood and collagenase activity. Its POC diagnostic tools use patented technology to analyze biometric markers in a single drop of blood, revealing insights into patient health. The company is based in Glen Allen, Virginia. For more information, visit the company's website at www.exactusinc.com.
Perma-Fix Environmental (PESI)
Perma-Fix Environmental (NASDAQ: PESI) is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the Department of Energy ("DOE"), the Department of Defense ("DOD"), and the commercial nuclear industry. Perma-Fix Environmental's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide. For more information, visit the company's website at www.perma-fix.com.
A-Mark Precious Metals (AMRK)
A-Mark Precious Metals (NASDAQ: AMRK) operates as a precious metals trading company worldwide. The company offers gold, silver, platinum and palladium in the form of bars, plates, powder, wafers, grains, ingots and coins, as well as distributes gold and silver coins and bars from sovereign and private mints. It also provides loans on precious metals, rare coins, and other collectibles collateral to coin dealers, collectors and investors; storage solutions for precious metals and numismatic coins for financial institutions, dealers, investors and collectors; and a range of logistics services. For more information, visit the company's website at www.amark.com.
Atossa Genetics (ATOS)
Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company engaged in the development of novel therapeutics and delivery methods to treat breast cancer and other breast conditions. The company's leading program utilizes patented intraductal microcatheters, which deliver pharmaceuticals through the breast milk ducts. In March 2016, Atossa initiated a Phase 2 clinical study of these microcatheters to deliver fulvestrant as a potential treatment for ductal carcinoma in-situ, or DCIS, and breast cancer. For more information, visit the company's website at www.atossagenetics.com.
CV Sciences (CVSI)
CV Sciences (OTC: CVSI) is a life science company that focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). The company operates through two segments: Specialty Pharmaceutical and Consumer Product. It also manufactures, markets and sells plant-based CBD products under PlusCBD brand for a range of market sectors, including nutraceutical, beauty care, specialty foods, and vape. The company was formerly known as CannaVEST Corp. and changed its name to CV Sciences in January 2016. CV Sciences was founded in 2010 and is based in Las Vegas, Nevada. For more information, visit the company's website at www.cvsciences.com.
Kindred Biosciences (KIN)
Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company that focuses on the development of therapies for pets. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. Its lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for the treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs associated with equine metabolic syndrome. For more information, visit the company's website at www.kindredbio.com.
Inpixon (NASDAQ: INPX) provides Indoor Positioning and Data Analytics. Inpixon sensors are designed to find all accessible cellular, Wi-Fi, and Bluetooth devices anonymously. Paired with a high performance, data analytics platform, this technology delivers visibility, security and business intelligence on any commercial or government premises world-wide. The company's products, infrastructure solutions, and professional services group help customers take advantage of mobile, big data, analytics, and the Internet of Things (IoT) to uncover the untold stories of the indoors. For more information, visit the company's website at www.inpixon.com.
MariMed (OTCQB: MRMD), formerly Worlds Online, is an industry leader in the design, development, operation, funding and optimization of medical cannabis cultivation and production centers and dispensaries. The company has developed state-of-the-art, regulatory-compliant facilities in multiple states that leverage a scalable model of excellence leaning on well-defined horticultural principles related to cannabis production, product development and dispensary operations. MariMed's turnkey solutions, including a wide array of management and advisory services, help cannabis cultivators, producers and dispensaries better address the needs of their patients by enabling the reliable production and delivery of high quality, tested cannabis flower and cannabis products. For more information, visit www.marimedadvisors.com.
Issuer Direct (ISDR)
Issuer Direct (NYSE: ISDR) provides disclosure management solutions, shareholder communications tools, and cloud-based compliance technologies in North America and Europe. It offers products and services that enable companies to produce and distribute their financial and business communications online and in print. The company provides Platform ID, a cloud-based communications and compliance system for corporate issuers, mutual funds and compliance professionals. Its disclosure management solutions consist of document conversion, typesetting, and pre-press design services, as well as XBRL tagging and stock transfer services. For more information, visit the company's website at www.issuerdirect.com.
Barfresh Food Group (BRFH)
Barfresh Food Group (OTC: BRFH) is a developer, manufacturer and distributor of ready-to-blend beverages, including smoothies, shakes and frappes, primarily for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages without waste that are quick and cost efficient. PepsiCo North America Beverages, a division of PepsiCo, Inc., is the exclusive sales representative in North America within the food service channel for Barfresh's full line of beverages. For more information, visit the company's website at www.barfresh.com.
NovaBay Pharmaceuticals (NBY)
NovaBay Pharmaceuticals (NYSE: NBY) is a pharmaceutical company that develops, manufactures and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. For more information, visit the company's website at www.novabaypharma.com.
Endexx (NASDAQ: EDXC) provides platforms for entrepreneurs. It offers medical marijuana management and technology solutions; m3Hub, a platform that manages patient concentric data and incorporates patient privacy practices through verification, privacy, legal and transparent controls; as well as legitimizes the entire transaction process on behalf of patients. Endexx also provides visual board books that offer an environment to create, deliver, edit, view, and review corporate data, as well as an interface to communicate and confer with approved parties. For more information, visit the company's website at www.endexx.com.
Finjan Holdings (FNJN)
Finjan Holdings (NASDAQ: FNJN) operates as a cybersecurity company that provides intellectual property licensing and enforcement services. The company owns a portfolio of patents related to software and hardware technologies that proactively detect malicious code and thereby protects end users from identity and data theft, spyware, malware, phishing, trojans and other web and network threats. Its patented technologies are used in specific cybersecurity technology areas, including endpoint/cloud software, web gateway/Internet infrastructure, networking equipment markets, and mobile security. The company's technology scans and repels the latest and unknown threats to network, web, and endpoint devices on a real-time basis. For more information, visit the company's website at www.finjan.com.
MaxPoint Interactive (MXPT)
MaxPoint Interactive (NASDAQ: MXPT) is a marketing technology company focused on generating hyperlocal intelligence in order to optimize brand and retail performance. The company's proprietary Digital Zip® technology, in combination with the MaxPoint Intelligence Platform™, predicts the most likely buyers for specific products at particular retail locations before executing cross-channel digital marketing programs designed to reach these buyers. Leveraging these tools, MaxPoint's clients are able to improve returns on their marketing budgets by quantifying accurate data regarding the effect of specific campaigns on purchases and optimizing advertising strategies in real time based on detailed reporting of product sales data, SKU-level sales lift, up-to-date inventory data and more. For more information, visit www.maxpoint.com.
Sensus Healthcare (SRTS)
Sensus Healthcare (NASDAQ: SRTS) manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameter. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. For more information, visit the company's website at www.sensushealthcare.com.
iCAD (NASDAQ: ICAD) is a pharmaceutical company that delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. The company offers a comprehensive range of upgradeable computer-aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. For more information, visit the company's website at www.icadmed.com.
CombiMatrix (NASDAQ: CBMX) provides clinical molecular diagnostic laboratory services in the United States. The company focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It provides molecular diagnostic services primarily in the areas of reproductive health for the diagnosis of developmental disorders associated with intellectual disability, congenital anomalies, dysmorphic features, and autism spectrum disorders. The company's testing focuses on advanced technologies, including single nucleotide polymorphism, chromosomal microarray analysis, sequencing, fluorescent in situ hybridization, and high resolution karyotyping. For more information, visit the company's website at www.combimatrix.com.
First Choice Healthcare Solutions (FCHS)
First Choice Healthcare Solutions (OTC: FCHS) engages in the provision of healthcare services in the United States. The company's network of non-physician-owned medical centers offer musculoskeletal and rehabilitative care services specializing in orthopaedics, spine surgery, neurology, interventional pain management and ambulatory surgical care. It also provides ancillary and diagnostic services comprising magnetic resonance imaging, X-ray, durable medical equipment, and rehabilitative care, including physical therapy and occupational therapy. In addition, the company owns, operates, and leases Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. For more information, visit the company's website at www.myfchs.com.
Navidea Biopharmaceuticals (NAVB)
Navidea Biopharmaceuticals (NYSE: NAVB) is a biopharmaceutical company that focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders. For more information, visit the company's website at www.navidea.com.
Her Imports (HHER)
Her Imports (OTC: HHER) is the world's largest importer of exotic human hair including Indian, Brazilian, Peruvian and Malaysian styles. It is the celebrity choice for premium quality virgin hair. The company offers luxury human hair extensions, lace and silk closures, lace frontals, 360 frontals, lace front wigs, full lace wigs, pro-grade cosmetics and accessories. It has stores in more than 30 cities across North America and Africa. Her Imports Brazilian Body Wave style hair offers a luxuriously soft, low maintenance install that will last 12-24 months with proper care. For more information, visit the company's website at www.herimports.com.
Inuvo (NYSE: INUV) operates as an Internet advertising technology and digital publishing company in the United States. It operates through two segments, Partner Network, and Owned and Operated Network. The company offers SearchLinks, a platform that delivers ads to digital publisher Webpages and apps using natural language technology to identify a site's content, subject matter, and context. It also provides ValidClick, software as a service and delivery platform that offers a pay-per-click solution where advertisements are targeted to consumers based on content and behaviors. For more information, visit the company's website at www.inuvo.com.
Full House Resorts (FLL)
Full House Resorts (NASDAQ: FLL) develops, owns, operates and manages casinos and related hospitality and entertainment facilities in regional U.S. markets. Based in Las Vegas, the company operates five casino facilities in Mississippi, Colorado, Indiana and Nevada. Each of its gaming properties reflects a unique atmosphere custom-designed for each regional market. Each of its casinos has a distinctive look and feel with the same goal: to provide our guests with the best experience in entertainment and customer service in an inviting, comfortable atmosphere. For more information, visit the company's website at www.fullhouseresorts.com.
Cemtrex (NASDAQ: CETX) provides electronic manufacturing services of electric system assemblies, instruments and emission monitors for industrial processes, and industrial air filtration and environmental control systems worldwide. The IPS segment provides a range of air filtration and environmental control products to various industrial and manufacturing industries, as well as monitoring instruments, software and systems for measurement of emissions of greenhouse gases, hazardous gases, particulate, and other regulated pollutants used in emissions trading. The EMS segment provides electronic manufacturing services, including product design and sustaining engineering services, printed circuit board assembly and production, cabling and wire harnessing, systems integration, comprehensive testing services, and assembled electronic products. For more information, visit the company's website at www.cemtrex.com.
Gemphire Therapeutics (GEMP)
Gemphire Therapeutics (NASDAQ: GEMP) is a clinical-stage biopharmaceutical company engaged in developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH. The company's focus is on providing new treatment options for cardiometabolic diseases through gemcabene, its complementary, convenient and cost-effective product candidate, as an add-on to the standard of care—particularly statins that will benefit patients, physicians and payors. The company has initiated three clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG). A fourth trial is planned to be initiated in NASH during the second half of 2017. For more information, visit the company's website at www.gemphire.com.
CopSync (NASDAQ: COYN) operates a real-time law enforcement mobile data information system in the United States. The company provides COPsync Network, a software as a service, which enables patrol officers to collect, report and share critical data in real-time at the point of incident and obtain instant access to various local, state and federal law enforcement databases. The company's COPsync Network service also enables officers to electronically write tickets; process DUI and other arrests; document accidents and other incidents; as well as allows dispatchers and officers to send be on the lookout and other alerts of child kidnappings, robberies, car thefts, police pursuits, and other crimes in progress to officers on the COPsync Network. For more information, visit the company's website at www.copsync.com.
PotNetwork Holdings (POTN)
PotNetwork Holdings (OTC: POTN) is a holding company for its subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils, and Sunrise Auto Mall, Inc. POTN is dedicated to the research, development, and multi-national marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives via its Diamond CBD subsidiary. POTN controls more than 15 CBD recognizable brands marketed at thousands of retail stores around the country. These products include CBD oils, edible gummies, vape pens, vape additives pet products, and more, and are available in 100s of flavors and sizes. For more information, visit the company's website at www.potnetworkholding.com.
Misonix (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices in the United States and internationally. The company provides medical devices that are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies including BoneScalpel, SonaStar, and SonicOne. For more information, visit the company's website at www.misonix.com.
Asterias Biotherapeutics (AST)
Asterias Biotherapeutics (NYSE: AST) is a pioneering biotechnology company in the field of regenerative medicine, offering proprietary cell therapy programs founded on pluripotent stem cell and immunotherapy platform technologies. Asterias is currently focused on advancing three clinical-stage programs with the potential to address areas of very high unmet medical need in the fields of neurology and oncology: AST-OPC1 (oligodendrocyte progenitor cells), currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury; AST-VAC1 (antigen-presenting autologous dendritic cells), being developed based on promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML); and AST-VAC2 (antigen-presenting allogeneic dendritic cells), which represents a second-generation, allogeneic cancer immunotherapy. For more information, visit the company's website at www.asteriasbiotherapeutics.com.
GrowGeneration (OTCQB: GRWG) is one of the largest operators of specialty retail hydroponic and organic gardening stores, offering products for both commercial and home cannabis growers. The company currently has 13 locations, including nine in Colorado, two in California, one in Nevada and one in Washington. Among the thousands of products GrowGen carries and sells, the company offers organic nutrients and soils, advanced lighting technology and cutting-edge hydroponic equipment for indoor and outdoor use. The company's mission is to own and operate GrowGeneration branded stores in all major legalized cannabis states. For more information, visit the company's website at www.growgeneration.com.
AmpliPhi Biosciences (APHB)
AmpliPhi Biosciences (NYSE: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi has reported final results from two phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus (S. aureus) in chronic rhinosinusitis patients and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi is also developing bacteriophage therapeutics targeting Pseudomonas aeruginosa (P. aeruginosa) and Clostridium difficile (C. difficile) in collaboration with a number of leading organizations focused on the advancement of bacteriophage-based therapies. For more information, visit www.ampliphibio.com.
LM Funding America (LMFA)
LM Funding America (NASDAQ: LMFA) operates as a specialty finance company that provides funding to nonprofit community associations primarily located in the state of Florida, as well as in the states of Washington, Colorado and Illinois. The company offers funding to associations by purchasing their rights under delinquent accounts that are selected by the associations arising from unpaid association assessments. It is also involved in the business of purchasing delinquent accounts on various terms tailored to suit each association's financial needs, including under its New Neighbor Guaranty program. For more information, visit the company's website at www.lmfunding.com.
Atomera (NASDAQ: ATOM) is a development-stage company that focuses on developing, commercializing and licensing proprietary processes and technologies for the semiconductor industry. It develops Mears Silicon Technology, or MST, a thin film of reengineered silicon that can be applied as a transistor channel enhancement to CMOS-type transistors in the semiconductor industry. The company was formerly known as Mears Technologies, Inc. and changed its name to Atomera Incorporated in January 2016. Atomera was founded in 2001 and is headquartered in Los Gatos, California. For more information, visit the company's website at www.atomera.com.
AzurRx BioPharma (AZRX)
AzurRx BioPharma (NASDAQ: AZRX) is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's therapeutic products will be administered to patients as oral non-systemic biologics. AzuRx currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France. For more information, visit the company's website at www.azurrx.com.
Synacor, Inc. (SYNC)
Synacor, Inc. (NASDAQ: SYNC) delivers modern, multiscreen experiences and advertising to their consumers that require scale, actionable data and sophisticated implementation. Reaching 120 million monthly visitors, 120 service providers, 3500 enterprises, 500 million email boxes and more than 1000 web publishers, Synacor's suite of multiscreen products and platforms and its advertising inventory provide a targeted means of extending its customers' brands and boosting their revenues. Synacor is headquartered in Buffalo, with offices in Boston, Dallas, London, New York, Ottawa, Pune, San Francisco, Singapore, Tokyo and Toronto. For more information, visit the company's website at www.synacor.com.
SenesTech, Inc. (SNES)
SenesTech, Inc. (NASDAQ: SNES) is the developer of an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach. The company's first fertility control product, ContraPest®, is marketed for use initially in controlling rat infestations. ContraPest is designed, formulated and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children. For more information, visit the company's website at www.senestech.com.
US Nuclear (UCLE)
US Nuclear (OTCBB: UCLE), through its subsidiaries, is engaged in operating two nuclear radiation detection companies: Overhoff Technology Corp. and Optron Scientific Company, Inc. US Nuclear designs, manufactures and markets branded, full-line radiation detection and specialized advanced tritium technology for the nuclear energy industry, as well as for emerging technological processes such as Thorium and Molten Salt (MSR) reactor technologies for domestic and international customers including U.S. Government Agencies, the U.S. Military, homeland security, scientific laboratories, universities, hospitals, nuclear reactor facilities in the United States, China, Canada, South Korea, Argentina, Russia and others. For more information, visit the company's website at www.usnuclearcorp.com.